Awaiting product image

Anti-Epidermal Growth Factor-like Protein 7 Antibody (90013)

$520.00

Host Quantity Applications Species Reactivity Data Sheet  
Mouse 100ug WB,IHC,ELISA Human
SKU: 90013 Categories: , ,
Overview
Product Name Anti-Epidermal Growth Factor-like Protein 7 Antibody (90013)
Description Anti-Epidermal Growth Factor-like Protein 7 Mouse Monoclonal Antibody
Target Epidermal Growth Factor-like Protein 7
Species Reactivity Human
Applications WB,IHC,ELISA
Host Mouse
Clonality Monoclonal
Clone ID 2H2
Isotype IgG1
Immunogen His-tagged EGFL-7 recombinant protein. Accession no. Q9UHF1.
Properties
Form Lyophilized
Formulation Lyophilized, 0.1M Tris, 0.1M glycine, 2% sucrose, 1mg/ml.
Buffer Formulation Tris Buffer
Format Purified
Purification Purified by Protein A affinity chromatography
Specificity Information
Specificity This antibody reacts with human EGFL- 7 protein.
Target Name Epidermal growth factor-like protein 7
Target ID Epidermal Growth Factor-like Protein 7
Uniprot ID Q9UHF1
Alternative Names EGF-like protein 7, Multiple epidermal growth factor-like domains protein 7, Multiple EGF-like domains protein 7, NOTCH4-like protein, Vascular endothelial statin, VE-statin, Zneu1
Gene Name EGFL7
Sequence Location Secreted, extracellular space
Biological Function Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis. {PubMed:23386126, PubMed:23639441}.
Research Areas Growth Factors, Cytokines, Receptors
Background EGF-L7 (Epidermal Growth Factor Like Protein 7) is a multi-domain protein containing two EGF like domains and one EMI domain. It is expressed almost exclusively in endothelial cells and functions to promote normal development of the vascular system. EGF-L7 is capable of antagonistic binding to Notch receptors resulting in the inhibition of Notch signaling in HUVEC and neural stem cells. In research models inducing hypoxia and subsequent reoxygenation, (H/R), EGF- L7 can inhibit ICAM-1 expression and enhance the inhibition of NF-kappaB activation. Additionally, EGF-L7 is a chemoattractant for endothelial cells and binds to the extracellular matrix. The overexpression of EGF-L7 is observed in various cancers, and is generally correlated with increased metastasis and a poor prognosis.
Application Images
Additional Information
Handling
Storage This product is stable for at least one (1) year at -20°C to -70°C. Reconstituted product should be stored in appropriate aliquots to avoid repeated freeze-thaw cycles.
Dilution Instructions Reconstitute lyophilized antibody using ultrapure to a final concentration no less than 100 ug/mL. Reconstitution with PBS or Tris buffer is acceptable if required. Protein carrier, biocide or cryopreservative can be added as needed. Aliquot and store at -20C for longterm storage. Dilute immediately prior to use.
Application Instructions ELISA: use at 1-10ug/ml

Immunoblotting:

User should use at 1-5ug/ml. A band of ~30kDa is detected.

Immunohistochemistry: Use at 2- 10ug/ml.

These are recommended concentrations.

End user should determine optimal concentrations for their applications.
References & Data Sheet